CYLENE PHARMACEUTICALS INITIATES CANCER TREATMENT TRIAL
Cylene Pharmaceuticals announced that it has initiated a Phase I clinical trial for CX-3543, its lead candidate for the treatment of multiple cancers. CX-3543 is a first-in-class small molecule with a novel mechanism of action that selectively induces cancer cell death. The clinical trial is being conducted at the Cancer Therapy and Research Center in San Antonio, Texas, and at the Mayo Clinic in Scottsdale, Ariz.
The clinical trial is currently open for enrollment and is designed to enroll approximately 36 patients with solid tumors or lymphomas. The objectives of the trial are to determine the safety and tolerability of CX-3543, to characterize its pharmacokinetic profile, to define dose-limiting toxicities and the maximum-tolerated dose, and to select the appropriate dose for Phase II trials.
Upcoming Events
-
21Oct